CY1120824T1 - Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων - Google Patents

Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων

Info

Publication number
CY1120824T1
CY1120824T1 CY181101159T CY181101159T CY1120824T1 CY 1120824 T1 CY1120824 T1 CY 1120824T1 CY 181101159 T CY181101159 T CY 181101159T CY 181101159 T CY181101159 T CY 181101159T CY 1120824 T1 CY1120824 T1 CY 1120824T1
Authority
CY
Cyprus
Prior art keywords
methods
proteins
recovery
contents
increasing
Prior art date
Application number
CY181101159T
Other languages
English (en)
Inventor
Jian Wu
Sean Davern
Simina Crina Petrovan
Michael Charles Brandenstein
Katherine Rose Lindahl
Shawn Erik Lillie
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50397323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120824(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CY1120824T1 publication Critical patent/CY1120824T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Abstract

Η παρούσα εφεύρεση σχετίζεται με μεθόδους διαμόρφωσης του περιεχομένου μαννόζης ανασυνδυασμένων πρωτεϊνών.
CY181101159T 2013-03-14 2018-11-06 Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων CY1120824T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784639P 2013-03-14 2013-03-14
PCT/US2014/022738 WO2014159259A1 (en) 2013-03-14 2014-03-10 Methods for increasing mannose content of recombinant proteins

Publications (1)

Publication Number Publication Date
CY1120824T1 true CY1120824T1 (el) 2019-12-11

Family

ID=50397323

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101159T CY1120824T1 (el) 2013-03-14 2018-11-06 Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων

Country Status (17)

Country Link
US (6) US9822388B2 (el)
EP (3) EP3434760B1 (el)
AR (1) AR095418A1 (el)
CY (1) CY1120824T1 (el)
DK (2) DK3434760T3 (el)
ES (2) ES2949507T3 (el)
FI (1) FI3434760T3 (el)
HR (1) HRP20230667T1 (el)
HU (2) HUE040682T2 (el)
LT (2) LT3434760T (el)
PL (2) PL3434760T3 (el)
PT (2) PT2970874T (el)
RS (1) RS64326B1 (el)
SI (2) SI2970874T1 (el)
TR (1) TR201815892T4 (el)
TW (4) TWI771890B (el)
WO (1) WO2014159259A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI120045B (fi) 2005-12-22 2009-06-15 Roal Oy Selluloosamateriaalin käsittely ja siinä käyttökelpoiset entsyymit
CN107988166B (zh) 2011-07-01 2022-03-15 美国安进公司 哺乳动物细胞培养
WO2013114245A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US11130980B2 (en) * 2013-10-31 2021-09-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
WO2017102794A1 (en) * 2015-12-15 2017-06-22 Csl Behring Recombinant Facility Ag Method for increasing the heterogeneity of o-glycosylation of recombinant factor vii
US11597911B2 (en) 2017-02-27 2023-03-07 Life Technologies Corporation Expansion of populations of T cells by the use of modified serum free media
US20200323958A1 (en) * 2017-11-13 2020-10-15 Amgen Inc. Methods for producing protein products
CA3085405A1 (en) 2017-12-20 2019-06-27 Ares Trading S.A. Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin
CA3099163A1 (en) * 2018-05-01 2019-11-07 Amgen Inc. Antibodies with modulated glycan profiles

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
JPH06292592A (ja) * 1993-02-09 1994-10-21 Snow Brand Milk Prod Co Ltd 糖蛋白質の生産方法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6673575B1 (en) * 1997-12-03 2004-01-06 Roche Diagnostics Gmbh Method for preparing polypeptides with appropriate glycosilation
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
AU2003249055B2 (en) * 2002-07-15 2008-06-26 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
DE102005046225B4 (de) 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
RU2011142230A (ru) 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
RU2013122843A (ru) 2010-10-20 2014-11-27 Морфотек, Инк. Гликоформы антитела против фолатного рецептора альфа
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2012149197A2 (en) * 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN107988166B (zh) * 2011-07-01 2022-03-15 美国安进公司 哺乳动物细胞培养
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9481901B2 (en) * 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins

Also Published As

Publication number Publication date
TW202311525A (zh) 2023-03-16
US20220213522A1 (en) 2022-07-07
PT2970874T (pt) 2018-11-16
EP4141104A1 (en) 2023-03-01
US11459595B2 (en) 2022-10-04
US11952605B2 (en) 2024-04-09
FI3434760T3 (fi) 2023-06-12
TWI625390B (zh) 2018-06-01
TW201831677A (zh) 2018-09-01
ES2949507T3 (es) 2023-09-29
PL3434760T3 (pl) 2023-09-11
US20220136026A1 (en) 2022-05-05
TWI720289B (zh) 2021-03-01
PL2970874T3 (pl) 2019-03-29
US20200087698A1 (en) 2020-03-19
LT2970874T (lt) 2018-12-10
LT3434760T (lt) 2022-06-27
HUE040682T2 (hu) 2019-03-28
TWI771890B (zh) 2022-07-21
AR095418A1 (es) 2015-10-14
DK2970874T3 (en) 2018-11-19
EP2970874A1 (en) 2016-01-20
SI3434760T1 (sl) 2022-08-31
US20180002733A1 (en) 2018-01-04
EP3434760A1 (en) 2019-01-30
PT3434760T (pt) 2022-07-05
SI2970874T1 (sl) 2019-01-31
US9822388B2 (en) 2017-11-21
EP3434760B1 (en) 2023-04-26
HRP20230667T1 (hr) 2023-10-13
DK3434760T3 (da) 2023-07-24
RS64326B1 (sr) 2023-08-31
US11319568B2 (en) 2022-05-03
EP2970874B1 (en) 2018-09-19
US20230193340A1 (en) 2023-06-22
TWI832345B (zh) 2024-02-11
TW201441368A (zh) 2014-11-01
US20160032343A1 (en) 2016-02-04
TW202142685A (zh) 2021-11-16
HUE063435T2 (hu) 2024-01-28
TR201815892T4 (tr) 2018-11-21
ES2691801T3 (es) 2018-11-28
WO2014159259A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
CY1120824T1 (el) Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
DOP2018000181A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
EA201690314A1 (ru) Анти-garp-белок и его применения
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA202092435A3 (ru) Моноклональные антитела против bcma
BR112016022841A2 (pt) cadeia j modificada
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
UY34885A (es) Proteínas de unión anti-mesotelina
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
UY34608A (es) Péptidos sintéticos de tránsito al cloroplasto.
MX2016016886A (es) Anticuerpos anti-axl.
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
MX2017007381A (es) Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
CY1122678T1 (el) Μορια συνδεσης προσδετη και χρησεις αυτων
EA201690992A1 (ru) Антитела, специфичные к fcrn
CY1124445T1 (el) Αντισωματα αντι-ccl17
DK3020732T3 (da) Immunoglobulin-Fc-konjugat, som bevarer immunoglobulin-Fc-fragmentets bindingsaffinitet til FcRn
EA201600093A1 (ru) Дигидроксифенильные нейромедиаторные соединения, композиции и способы
EA201691269A1 (ru) Дерматологическая композиция на основе экстрактов водорослей и листа оливы
SE1530091A1 (el)